Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAG | P20916 | 4/20 | 0.36 |
| ▸ | CD22 | P20273 | 5/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084278 | 1.00 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL17546165 | 1.00 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL16348268 | 1.00 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL14944652 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL16348273 | 0.85 | MAG (0.41) | L3MBTL1MAGCD22 | |
| SCHEMBL31500844 | 0.84 | MAG (0.52) | L3MBTL1MAGCD22NEU1NEU2 | |
| SCHEMBL30481193 | 0.84 | MAG (0.52) | L3MBTL1MAGCD22NEU1NEU2 | |
| SCHEMBL25702221 | 0.84 | MAG (0.52) | L3MBTL1MAGCD22NEU1NEU2 | |
| SCHEMBL27977966 | 0.84 | MAG (0.52) | L3MBTL1MAGCD22NEU1NEU2 | |
| SCHEMBL14946228 | 0.84 | MAG (0.52) | L3MBTL1MAGCD22NEU1NEU2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103974965-B | Sialic acid analogues | 奥特吉尼克斯制药公司 | 2019-09-24 | — | — | CN | disclosed |